



Somerset Therapeutics and Affiliate Wintac, Limited to be Acquired by Endo

Torrey advised Somerset on Sale

Somerset, NJ USA and Dublin, Ireland, April 26, 2018

Somerset Therapeutics, a New Jersey based specialty pharmaceutical company that develops and markets sterile injectable and ophthalmic drugs for the U.S. marketplace, and its India based affiliate Wintac, which operates as its contract developer and manufacturer, will be acquired by Endo International. Endo will pay approximately \$190 million for both companies.

The acquisition of Somerset Therapeutics expands Endo's portfolio of sterile injectable products and their injectable and ophthalmic Research & Development capabilities. Additionally, Wintac's strong Research & Development capabilities and high-quality manufacturing capabilities expand Endo's manufacturing capacity.

Torrey served as financial advisor to Somerset Therapeutics on this transaction. This transaction highlights Torrey's expertise in the generic pharmaceutical sector and its focus on assisting in complex cross-border transactions. The transaction represents Torrey's 7th completed transaction in 2018 and the 8th completed transaction involving a party in India in the past 12 months.

ABOUT SOMERSET THERAPEUTICS, LLC:

For more information about Somerset, please see:

<http://go.pardot.com/e/352371/2018-04-26/464sk/21120338>

ABOUT ENDO INTERNATIONAL PLC:

For more information about Endo, please see: [http://go.pardot.com/e/352371/2018-](http://go.pardot.com/e/352371/2018-04-26/464sm/21120338)

[04-26/464sm/21120338](http://go.pardot.com/e/352371/2018-04-26/464sm/21120338)

Deal Press Release

TORREYA CONTACT

Allen Lefkowitz

Managing Director | New York Office

allen.lefkowitz@torreya.com | 212.257.5823 | torreya.com

Torrey is a global advisory firm serving the life sciences industry. Please visit torreya.com for more information. Securities offered in the United States are offered through Torrey Capital LLC, Member FINRA/SIPC. Torrey Partners LLC is a Delaware Limited Liability Company while Torrey Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torrey Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torrey Capital and its



and affiliate
Wintac, Limited
acquired by



\$190 million
April 2018